Histopathological Features Of Endocardial Fibroelastosis: Microscopic Diagnosis
Published on: February 12, 2026
Histopathological Features of Endocardial Fibroelastosis Microscopic Diagnosis featured image
  • Article author photo

    Saranya Arulrajah

    BSc Biomedical Science (Undergraduate), University of Roehampton, London

Overview 

Endocardial fibroelastosis (EFE) is a rare cardiac condition characterised by the abnormal thickening of the endocardium due to excessive deposition of collagen and elastic fibers.1 This thickening reduces the elasticity and compliance of the ventricular wall, restricting diastolic filling and eventually leading to heart failure, particularly in infants and young children.2 The disease can occur as a primary condition, developing idiopathically without underlying structural abnormalities, or as a secondary manifestation in association with congenital heart anomalies such as aortic stenosis, aortic valve atresia, hypoplastic left heart syndrome, or following post-infectious cardiac injury.

Although EFE has become less common in recent decades, largely due to advances in prenatal cardiac imaging and early surgical correction of congenital defects, it remains an important clinical entity. Prompt recognition is essential, as delayed diagnosis often results in progressive ventricular dysfunction. Definitive confirmation of the disease relies on histopathological evaluation, which enables direct visualisation of the characteristic fibrous and elastic changes that may not always be detectable through imaging alone.3

What is Endocardial Fibroelastosis? 

Endocardial fibroelastosis refers to a pathological process involving diffuse thickening of the endocardium caused by the accumulation of collagen and elastic fibres.4 The resulting stiffened endocardial layer interferes with normal ventricular compliance, which impairs cardiac filling and function.

Classification 

EFE can be broadly divided into primary and secondary forms, depending on its origin and associated cardiac abnormalities.

Primary EFE

Primary EFE represents the idiopathic form of the disease. It is extremely rare and typically occurs in infants younger than one year. Genetic factors may play a role, as some familial cases have been linked to mutations in genes regulating the cardiac extracellular matrix. Infants with primary EFE commonly present with signs of congestive heart failure, tachypnea, difficulty feeding, hepatomegaly, and failure to thrive are characteristic clinical findings.1 The condition may progress rapidly if not identified and managed early.

Secondary EFE

The secondary form is more common and is frequently associated with congenital heart defects, particularly left-sided obstructive lesions such as congenital mitral stenosis, aortic valve atresia, or hypoplastic left heart syndrome.5 In these situations, the fibroelastic thickening develops as a reactive response to increased endocardial stress and altered hemodynamics. Over time, these mechanical forces stimulate fibroblast proliferation and excess matrix deposition. Secondary EFE can also occur following viral myocarditis, intrauterine infections, or metabolic disorders, all of which may trigger a similar cascade of endocardial injury and repair.

Pathophysiology 

The pathogenesis of EFE is complex and multifactorial. It involves abnormal activation of cardiac fibroblasts, which deposit excessive amounts of type I and III collagen along with elastin fibres in the subendocardium. The initiating mechanisms may include hemodynamic stress, inflammation, or inherited genetic abnormalities.

In cases linked to congenital defects, turbulent blood flow and increased ventricular pressure cause mechanical stress that promotes fibroblast activation. In others, inflammatory mediators such as cytokines can stimulate fibroblast proliferation and matrix synthesis. Rare familial cases may exhibit autosomal recessive or X-linked inheritance patterns.

As the endocardium thickens, ventricular compliance decreases, and diastolic filling becomes impaired. This process increases myocardial workload, often leading to compensatory hypertrophy of the underlying cardiomyocytes. Eventually, chronic stiffness and reduced chamber volume can result in restrictive cardiomyopathy, a severe condition that may ultimately require cardiac transplantation in advanced cases.9

Histopathological Features 

Histopathological examination remains the gold standard for diagnosing EFE. A combination of gross and microscopic analysis, supported by special stains, allows for detailed assessment of fibrous and elastic tissue changes.

Gross examination 

On gross inspection, the affected endocardium appears diffusely thickened, smooth, and pale or glistening white.3 The changes are most evident in the left ventricle, particularly in the inflow tracts and apical regions. Papillary muscles often appear flattened and may be partially incorporated into the fibrotic layer. The ventricular wall can appear hypertrophied, but typically, there is no evidence of overt myocardial necrosis. These macroscopic features, while characteristic, are not diagnostic on their own and require microscopic confirmation.

Microscopic examination 

Under the microscope, EFE is defined by distinct subendocardial fibrosis and elastic fibre proliferation. The subendocardial region contains densely packed, often acellular collagen bundles5. Fibroblasts may be sparse or focally increased, depending on disease stage. Collagen deposition forms a rigid, unyielding matrix that contributes to ventricular stiffness.

Elastic fibres are irregularly arranged and interspersed among the collagen bundles. They may appear in lamellar or reticular formations, reinforcing the fibrotic layer. Beneath this thickened endocardium, the myocardium typically shows mild hypertrophy of cardiomyocytes due to increased workload. Small clusters of lymphocytes may be present, particularly in secondary cases associated with congenital defects or viral infection. Despite these changes, myocardial necrosis and scarring are generally absent. Small intramural blood vessels may show reactive endothelial proliferation, but significant vasculopathy is not a feature of this condition.

Special stains 

Special histological stains are essential for distinguishing the components of the fibrotic and elastic matrix.

  • Masson’s Trichrome stain highlights collagen fibres in blue, contrasting with the red-stained myocardium, and is particularly useful for assessing the extent of fibrosis6
  • Elastic Van Gieson stain colours elastic fibres black against a pink background, clearly illustrating their distribution and density
  • Hematoxylin and Eosin (H&E) provides general tissue architecture, while Picrosirius Red enhances visualisation of collagen under polarised light

Together, these stains provide a detailed and reliable visual confirmation of EFE, distinguishing it from other fibrotic cardiac disorders.

Clinical and diagnostic considerations 

Presenation 

EFE most often presents in infancy with symptoms of heart failure. Affected infants may show tachypnea, dyspnea, hepatomegaly, and poor feeding. Cardiomegaly is a frequent finding on chest X-ray or echocardiography. In some cases, a prenatal ultrasound may reveal ventricular thickening and hypokinesis, allowing for suspicion of EFE before birth.

Imaging 

Imaging techniques play a central role in evaluating EFE.

  • Echocardiography is the primary diagnostic tool, demonstrating diffuse endocardial thickening, reduced ventricular compliance, and decreased contractility
  • Cardiac MRI provides detailed tissue characterisation, helping identify areas of fibrosis and assess myocardial involvement
  • CT scanning is used less often but may contribute to structural assessment when other modalities are inconclusive

Differential diagnosis 

EFE must be differentiated from other causes of endocardial or myocardial thickening, including primary restrictive cardiomyopathy, endocardial thrombus, myocardial fibrosis due to ischemia or myocarditis, and metabolic or storage disorders such as glycogen storage diseases or mucopolysaccharidoses.7 Histopathological examination is often the decisive step in distinguishing EFE from these conditions.

Prognosis 

The prognosis of EFE varies considerably depending on whether it is primary or secondary. In primary EFE, some infants respond to medical therapy and show improvement over time, while others experience relentless progression to heart failure. In secondary forms, the overall outlook largely depends on the underlying congenital lesion; surgical correction of the defect can lead to significant improvement. However, severe or refractory cases may require heart transplantation as the definitive treatment option.

Pathogenesis insights from recent studies 

Recent molecular studies have provided new insights into the mechanisms underlying EFE. Evidence suggests that abnormal activation of fibroblasts and dysregulation of extracellular matrix turnover play central roles. Increased activity of transforming growth factor-beta (TGF-β) signalling appears to promote collagen synthesis and deposition, while altered expression of elastin-related genes contributes to the abnormal proliferation of elastic fibres. Inflammatory cytokines triggered by viral infections or congenital abnormalities can further amplify these processes, driving persistent endocardial remodelling. Understanding these molecular pathways opens the door to potential therapeutic targets aimed at preventing or limiting fibrotic progression in EFE.

Histopathological challenges

Diagnosing EFE can be difficult because of its rarity and the nonspecific nature of its clinical presentation.8 Symptoms frequently overlap with other forms of paediatric heart failure, and imaging findings may be subtle or inconclusive. Moreover, EFE shares histological similarities with other fibrotic cardiac conditions, such as post-myocarditis fibrosis or endocardial thickening secondary to congenital malformations. Therefore, accurate diagnosis requires an integrated approach combining clinical history, imaging data, and confirmatory histopathological examination.

Management implications 

While histopathology serves primarily as a diagnostic tool, it also informs patient management. Confirming EFE histologically supports the need for medical therapy to manage heart failure, typically involving diuretics, inotropes, and afterload reduction. The findings can also help determine the appropriate timing for surgical correction of any underlying congenital anomaly. In recurrent or familial cases, histological confirmation provides valuable prognostic information and may prompt genetic counselling for affected families.

FAQs

Is Endocardial Fibroelastosis the same as Endomyocardial Fibrosis?

No. Although they sound similar, endocardial fibroelastosis (EFE) primarily involves diffuse thickening of the endocardium due to collagen and elastin deposition, whereas endomyocardial fibrosis is a restrictive cardiomyopathy often seen in tropical regions with endocardial scarring and calcification.

How is EFE differentiated from other cardiac pathologies?

EFE can mimic other causes of endocardial thickening, such as restrictive cardiomyopathy or myocarditis. However, its hallmark is the concentric, acellular deposition of collagen and elastic tissue in the endocardium, without the inflammatory or necrotic features seen in myocarditis.

What are the clinical implications of identifying EFE histologically?

Histopathological confirmation of EFE helps in guiding management, as the condition is associated with poor cardiac compliance, progressive heart failure, and high infant mortality if untreated. Early recognition is crucial for considering interventions such as cardiac transplantation.

Is EFE always congenital?

No. While it often presents in infants and young children, acquired cases have been described in association with viral myocarditis, idiopathic dilated cardiomyopathy, and obstructive left heart lesions.

What is the clinical importance of diagnosing EFE histologically?

Histological confirmation helps distinguish EFE from other cardiomyopathies, guiding appropriate management, genetic counselling, and prognosis.

Summary

Endocardial fibroelastosis (EFE) is a rare cardiac condition characterised by the deposition of collagen and elastic fibres in the endocardium, leading to thickening. This condition predominantly affects infants and young children and is often associated with restrictive cardiomyopathy. Histopathological examination plays a crucial role in diagnosing EFE, providing insights into its microscopic features. Diagnosing EFE can be challenging due to its rarity and nonspecific symptoms, requiring a comprehensive approach.

References

  1. Alina Costina Luca. Endocardial fibroelastosis and dilated cardiomyopathy – the past and future of the interface between histology and genetics. Romanian Journal of Morphology and Embryology [Internet]. 2021 Jun 25;61(4):999–1005. Available from: https://pubmed.ncbi.nlm.nih.gov/34171049/
  2. Sobieh A, Bolen MA, Rodriguez ER, Tan CD, Rodriquez LL, Renapurkar RD. Multimodality Imaging and Pathologic Assessment in an Adult with Endocardial Fibroelastosis. CASE [Internet]. 2017 Aug 3;1(5):176–8. Available from: https://www.sciencedirect.com/science/article/pii/S2468644117300348#fig5
  3. Mohan BP, Rajendraprasad VK, Parthasarathy KS, Zacharia TT. Endocardial fibroelastosis causing sudden death in an infant: Autopsy case report of an unusual lesion. Indian journal of pathology & microbiology [Internet]. 2024 Jan;67(3):665–8. Available from: https://pubmed.ncbi.nlm.nih.gov/38391319/
  4. Clark ES, Pepper VK, Best CA, Onwuka EA, Yi T, Tara S, et al. A mouse model of endocardial fibroelastosis. Cardiovascular Pathology [Internet]. 2015 Aug 8 [cited 2025 Aug 28];24(6):388–94. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC4747030/
  5. Zhang H, Huang X, Liu K, Tang J, He L, Pu W, et al. Fibroblasts in an endocardial fibroelastosis disease model mainly originate from mesenchymal derivatives of the epicardium. Cell Research [Internet]. 2017 Sep 1;27(9):1157–77. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5587848/
  6. Weixler V, Marx GR, Hammer PE, Emani SM, del Nido PJ, Friehs I. Flow disturbances and the development of endocardial fibroelastosis. The Journal of Thoracic and Cardiovascular Surgery [Internet]. 2019 Sep 26;159(2):637–46. Available from: https://www.sciencedirect.com/science/article/pii/S0022522319319014
  7. Leeuw N de, Ruiter DJ, Balk M, Nicolaas de Jonge, W. J. G. Melchers, Jochem. Histopathologic findings in explanted heart tissue from patients with end-stage idiopathic dilated cardiomyopathy. Transplant International. 2001 Sep 1;14(5):299–306.
  8. Angelini A, Vittorio Calzolari, Gaetano Thiene, Boffa GM, Valente M, Daliento L, et al. Morphologic spectrum of primary restrictive cardiomyopathy. The American Journal of Cardiology [Internet]. 1997 Oct 1 [cited 2025 Aug 28];80(8):1046–50. Available from: https://www.ajconline.org/article/S0002-9149(97)00601-2/abstract
  9. Poothirikovil Venugopalan, MBBS, MD, FRCPCH. Endocardial Fibroelastosis: Background, Pathophysiology, Etiology [Internet]. Medscape.com. Medscape; 2024. Available from: https://emedicine.medscape.com/article/896375-overview
  10. Sana MK, Mahajan K. Endocardial Fibroelastosis [Internet]. PubMed. Treasure Island (FL): StatPearls Publishing; 2022. Available from: https://www.ncbi.nlm.nih.gov/books/NBK559128/

Share

Saranya Arulrajah

BSc Biomedical Science (Undergraduate), University of Roehampton, London

Saranya is a Biomedical Science student with an interest in research and healthcare. She has completed a summer internship with the Wellcome Trust at King’s College London, gaining valuable insight into the biomedical research field. Alongside her studies, she has undertaken work experience in a pharmacy and works as tutor, supporting students in their academic development.

arrow-right